Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 15;2012(2):CD009007.
doi: 10.1002/14651858.CD009007.pub2.

Blood transfusions for anaemia in patients with advanced cancer

Nancy J Preston  1 , Adam Hurlow, Jennifer Brine, Michael I Bennett
Affiliations

Blood transfusions for anaemia in patients with advanced cancer

Nancy J Preston et al. Cochrane Database Syst Rev. .

Abstract

Background: Anaemia occurs in 68% to 77% of patients with advanced cancer, however, only a minority of patients who are admitted to a hospice receive a blood transfusion. It is unclear what the benefit of blood transfusion is in advanced cancer, who is most likely to respond and also for how long. Hence we conducted a systematic review to assess the use of blood transfusion in advanced cancer.

Objectives: To synthesise the existing clinical evidence and summarise knowledge gaps regarding blood transfusions for treating anaemia in patients with advanced cancer.

Search methods: We searched MEDLINE, EMBASE, CINAHL, Web of Science, ZETOC and CENTRAL in November 2011. In addition, we checked and citation-tracked the reference lists of all relevant studies and reports. We contacted investigators who were known to be researching this area for unpublished data or knowledge of the grey literature.

Selection criteria: Randomised controlled trials (RCTs), before and after studies and interrupted time series (ITS) studies in adults and children, reporting the outcome of blood transfusions in advanced cancer.

Data collection and analysis: Two independent (NP and AH) review authors extracted data and quality scored studies. There were insufficient data to carry out an analysis.

Main results: No RCTs were found. We identified 12 before and after studies which included 653 participants and showed a subjective response rate of 31% to 70%. Five studies specifically assessed response using a range of fatigue scales which indicated an early response post transfusion, which was beginning to wane by day 14. Similar results were found for breathlessness. Overall survival ranged from two to 293 days but there was a significant proportion of participants (23% to 35%) who died within two weeks of their transfusion.

Authors' conclusions: Higher-quality studies are required to determine the effectiveness of blood transfusion at the end of life and, in particular, to determine which patients are most likely to respond and which are not, and the duration of any response. Potential harms of blood transfusion at the end of life (indicated by high 14-day mortality) need to be distinguished from inappropriate transfusion in patients who are dying from advanced cancer.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

  • doi: 10.1002/14651858.CD009007

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Brown 2007 {published data only}
    1. Brown E, Bennett M. Survey of blood transfusion practice for palliative care patients in Yorkshire: implications for clinical care. Journal of Palliative Medicine 2007;10:919‐22. - PubMed
Brown 2010 {published data only}
    1. Brown E, Hurlow A, Rahman A, Closs SJ, Bennett MI. Assessment of fatigue after blood transfusion in palliative care patients: a feasibility study. Journal of Palliative Medicine 2010;13:1327‐30. - PubMed
Gleeson 1995 {published data only}
    1. Gleeson C, Spencer D. Blood‐transfusion and its benefits in palliative care. Palliative Medicine 1995;9:307‐13. - PubMed
Laird 2008 {published data only}
    1. Laird BJA, Whyte G, Laird JH, Soutar RL, Welsh J, Fallon MT. An observational study of red cell transfusion in specialist palliative care. Palliative Medicine 2008;22:874‐5. - PubMed
Lau 2006 {published data only}
    1. Lau SC, Tsai WYCCH. Comparison of outcomes of blood transfusion in non‐hospice and hospice terminal cancer patients in a district hospital. Fu‐Jen Journal of Medicine 2006;4:83‐9.
Mercadante 2009 {published data only}
    1. Mercadante S, Ferrara P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia‐related symptoms in patients with cancer. Journal of Palliative Medicine 2009;12:60‐3. - PubMed
Monti 1996 {published data only}
    1. Monti M, Castellani L, Berlusconi A, Cunietti E. Use of blood transfusions in terminally ill cancer patients admitted to a palliative care unit. Journal of Pain and Symptom Management 1996;12:18‐22. - PubMed
Morey 2003 {published and unpublished data}
    1. Morey PJ. Blood transfusion in palliative care ‐ who benefits?. European Association for Palliative Care 8th Congress, The Hague. 2003.
Tanneberger 2004 {published data only}
    1. Tanneberger S, Melilli G, Strocchi E, Frenquelli C, Pannuti QF. Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer‐related anaemia controlled better with erythropoietic agents?. Annals of Oncology 2004;15:839‐44. - PubMed
Vassallo 2006 {published data only}
    1. Vassallo E, Piccione T, Pirajno G, Palazzolo B, Trizzino G. Miglioramento della qualità di vita in pazienti terminali con anemia severa sottoposti a trasfusione domiciliare. Rivista Italiana di Cure Palliative 2006;4:30‐6.
Wachtel 1985 {published data only}
    1. Wachtel T, Mor V. The use of transfusion in terminal cancer patients. Hospice versus conventional care setting. Transfusion 1985;25:278‐9. - PubMed
Yang 2011 {published and unpublished data}
    1. Yang GM, Light D, Bengston KA. Indications and benefits of blood transfusions in a hospice setting. European Journal of Palliative Care. 2011; Vol. 18:256‐7.

References to studies excluded from this review

Martinsson 2009 {published data only}
    1. Martinsson U, Lundström S. The use of blood transfusions and erythropoietin‐stimulating agents in Swedish palliative care. Supportive Care in Cancer 2009;17:199‐203. - PubMed

Additional references

Abernethy 2003
    1. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327(7414):523. - PMC - PubMed
American Thoracic Society 1999
    1. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Journal of Respiratory Critical Care Medicine 1999;159:321‐40. - PubMed
Anon 2009
    1. Anon. NHS blood and transplant saving lives together. Annual Review 2008/2009 2009:13‐4.
Basha 2006
    1. Basha J, Dewitt RC, Cable D, Jones GP. Transfusions and their costs: managing patients needs and hospitals economics. The Internet Journal of Emergency and Intensive Care Medicine 2006;9(2):www.ispub.com/ostia/index.php?xmlPrinter=true&xmlFilePath=journals/i....
Bausewein 2008
    1. Bausewein C, Booth S, Gysels M, Higginson I. Non‐pharmacological interventions for breathlessness in advanced stages of malignant and non‐malignant diseases. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005623.pub2] - DOI - PubMed
Bruera 2000
    1. Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. Journal of Pain and Symptom Management 2000;19(5):357‐62. - PubMed
Cella 2001
    1. Cella D, Davis K, Breitbart W, Curt G. Cancer‐related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology 2001;19(14):3385. - PubMed
Chan 2005
    1. Chan KS, Sham MMK, Tse DMW, Thorsen AB. Palliative medicine in malignant respiratory diseases. In: Doyle D, Hanks G, Cherny N, Calman K editor(s). Oxford Textbook of Palliative Medicine. 3rd Edition. Vol. 3, Oxford University Press, 2005:587‐618.
Conill 1997
    1. Conill C, Verger E, Henríquez I, Saiz N, Espier M, Lugo F, et al. Symptom prevalence in the last week of life. Journal of Pain and Symptom Management 1997;14(6):328‐31. - PubMed
Cramp 2008
    1. Cramp F, Daniel J. Exercise for the management of cancer‐related fatigue in adults. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006145.pub2] - DOI - PubMed
Cremieux 2000
    1. Cremieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology 2000;18(14):2755. - PubMed
Demetri 1998
    1. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality‐of‐life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Journal of Clinical Oncology 1998;16(10):3412. - PubMed
Dorman 2007
    1. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliative Medicine 2007;21(3):177. - PubMed
Dudgeon 1998
    1. Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. Journal of Pain and Symptom Management 1998;16(4):212‐9. - PubMed
Dunn 2003
    1. Dunn A, Carter J, Carter H. Anemia at the end of life: prevalence, significance, and causes in patients receiving palliative care. Journal of Pain and Symptom Management 2003;26(6):1132‐9. - PubMed
EPOC 1998
    1. EPOC methods paper including interrupted time series (ITS) designs in a EPOC review. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/inttime.pdf 1998.
Falk 2006
    1. Falk K, Swedberg K, Gaston‐Johansson F, Ekman I. Fatigue and anaemia in patients with chronic heart failure. European Journal of Heart Failure 2006;8(7):744. - PubMed
Gabrilove 2001
    1. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once‐weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three‐times‐weekly dosing. Journal of Clinical Oncology 2001;19(11):2875. - PubMed
Glaspy 1997
    1. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan‐Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology 1997;15(3):1218. - PubMed
Hwang 2003
    1. Hwang SS, Chang VT, Rue M, Kasimis B. Multidimensional independent predictors of cancer‐related fatigue. Journal of Pain and Symptom Management 2003;26(1):604‐14. - PubMed
Indelicato 2006
    1. Indelicato RA. The advanced practice nurse's role in palliative care and the management of dyspnea. Topics in Advanced Practice Nursing eJournal 2006;6(4):Accessed on 12 January 2011 from: http://search.medscape.com/medscape‐search?queryText=indelicato.
Izaks 1999
    1. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in older persons. JAMA 1999;281(18):1714‐7. - PubMed
Jennings 2001
    1. Jennings AL, Davies AN, Higgins JPT, Anzures‐Cabrera J, Broadley KE. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002066] - DOI - PubMed
Ledingham 1977
    1. Ledingham IM. Factors influencing oxygen availability. Journal of Clinical Pathology 1977;3(1):1. - PMC - PubMed
Littlewood 2001
    1. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Oncology 2001;19(11):2865. - PubMed
McClelland 2007
    1. McClelland DBL. Handbook of Transfusion Medicine. Vol. 12, Crown, 2007:390.
Meek 2003
    1. Meek PM, Lareau SC. Critical outcomes in pulmonary rehabilitation: assessment and evaluation of dyspnea and fatigue. Journal of Rehabilitation Research and Development 2003;40(5 (Suppl 2)):13‐24. - PubMed
Mendoza 1999
    1. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients. Cancer 1999;85(5):1186‐96. - PubMed
Minton 2010
    1. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer‐related fatigue. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub3] - DOI - PubMed
Mock 2007
    1. Mock V, Abernathy AP, Atkinson A, Barsevick AM, Berger AM, Cella D. NCCN Clinical Practice Guidelines in Oncology. Cancer‐related fatigue. Journal of the National Comprehensive Cancer Network 2007;5:1054‐78. - PubMed
Morgan 2010
    1. Morgan K. Fatigue and lethargy in palliative care. InnovAit 2010;3(4):225.
Nekolaichuk 2008
    1. Nekolaichuk C, Watanabe S, Beaumont C. The Edmonton Symptom Assessment System: a 15‐year retrospective review of validation studies (1991‐2006). Palliative Medicine 2008;22(2):111‐22. - PubMed
Noergaard Munch 2005
    1. Noergaard Munch T, Zhang Z, Willey J, Lynn Palmer J, Bruera E. The association between anaemia and fatigue in patients with advanced cancer receiving palliative care. Journal of Palliative Medicine 2005;8:1144‐9. - PubMed
Reuben 1986
    1. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Pharmacotherapy 1986;89(2):234. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Schwartz 2002
    1. Schwartz AH. Validity of cancer‐related fatigue instruments. Pharmacotherapy 2002;22(11):1433‐41. - PubMed
Shafqat 2005
    1. Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, et al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Annals of Oncology 2005;16(9):1545. - PubMed
Sood 2005
    1. Sood A, Moynihan TJ. Cancer‐related fatigue: an update. Current Oncology Reports 2005;7(4):277‐82. - PubMed
Spathis 2009
    1. Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliative Medicine 2009;23(4):325. - PubMed
Stone 1999
    1. Stone P, Hardy J, Broadley K, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled cross‐sectional study. British Journal of Cancer 1999;79(9/10):1479. - PMC - PubMed
Stone 2000
    1. Stone P, Richards M, A'hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of Oncology 2000;11(5):561. - PubMed
Sweeney 2005
    1. Sweeney C, Neuenschwnader H, Bruera E. Fatigue and asthenia. Oxford Textbook of Palliative Medicine. 3rd Edition. Oxford University Press, 2005:560‐6.
Turner 2005
    1. Turner A. Clinical management of anemia, cytopenias and thrombosis in palliative medicine. Oxford Textbook of Palliative Medicine. 3rd Edition. Oxford University Press, 2005:568‐72.
Varney 2003
    1. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfusion Medicine 2003;13(4):205‐18. - PubMed
Wells 2002
    1. Wells AW, Mounter PJ, Chapman CE, Stainsby D, Wallis JP. Where does blood go? Prospective observational study of red cell transfusion in north England. BMJ 2002;325(7368):803. - PMC - PubMed
Yellen 1997
    1. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia‐related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management 1997;13(2):63‐74. - PubMed
Yennurajalingam 2007
    1. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "It feels like my body is just worn out". JAMA 2007;297(3):295. - PubMed

Publication types